Third Quarter 2025 Performance - The company's operating income increased by 6% to $113 million, based on revenue of $136 billion[29] - Comparable sales increased by 4%[28] - Aerie's comparable sales increased by 11%[28] - Earnings per diluted share (EPS) were $053[28] - The company repurchased shares totaling $231 million in the first half of the year, including $21 million this quarter, and returned $64 million in cash dividends year-to-date[29] Fiscal Year 2025 Outlook - The company anticipates comparable sales to be up in the low single digits[30] - The company expects operating income to be between $303 million and $308 million on an adjusted basis[30] - The company projects depreciation and amortization to be approximately $216 million[30] Inventory - Ending inventory increased by 11% to $891232 thousand compared to the previous year[39]

Financial Performance - The company reported revenue of $244 million, representing a 25% year-over-year growth rate[7, 41] - The Q3 FY26 Non-GAAP operating margin was 18%[7, 41] - The Q3 FY26 Non-GAAP adjusted free cash flow margin was 11%[7, 41] - Adjusted Free Cash Flow was $27 million[41] - The company's dollar-based net retention rate was 119%[7] - The company has provided revenue guidance for Q4 FY2026 of $2510 million to $2520 million and full fiscal year 2026 revenue guidance of $946 million to $947 million[52] Customer Base - The company has 10,475 base customers[7] - The company has 1,405 customers with over $100K in ARR[7] - 54% of total ARR is from GitLab Ultimate as of Q3 FY26[15] Product and Recognition - GitLab Ultimate is the company's AI-native enterprise-grade DevSecOps solution[15] - GitLab received Gartner recognition in the 2025 Magic Quadrant for DevOps Platforms and AI Code Assistants[20, 21]

Bank of America Leveraged Finance Presentation Curt Begle - Chief Executive Officer Jim Till- Chief Financial Officer Robert Weilminster – EVP Investor Relations 1 December 2025 Safe Harbor Statements and Important Information Magnera Corporation (NYSE: MAGN) serves 1,000+ customers worldwide, offering a wide range of material solutions, including components for absorbent hygiene products, protective apparel, wipes, specialty building and construction products, and products serving the food and beverage ind ...

UBS GLOBAL INDUSTRIALS & JIM VENA – CHIEF EXECUTIVE OFFICER JENNIFER HAMANN – CHIEF FINANCIAL OFFICER KENNY ROCKER – EVP MARKETING & SALES UNION PACIFIC CORPORATION TRANSPORTATION CONFERENCE UP-NS Merger: Path to Completion The Board of Directors of both Union Pacific and Norfolk Southern have unanimously approved the transaction STB application anticipated to be filed before the end of the year; analyst conference call to follow Transaction subject to obtaining Surface Transportation Board ("STB") approval ...

BANK OF AMERICA LEVERAGED FINANCE CONFERENCE DECEMBER 2025 © 2025 OPTION CARE HEALTH, INC. ALL RIGHTS RESERVED Disclaimers Forward-Looking Statements This presentation may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to fut ...

Oral Small Molecule Splicing Platform - PTC pioneered small molecule splicing therapies, with Evrysdi approved in over 100 countries and votoplam in development for Huntington's disease[21] - Small molecules enhance U1 interaction, increasing exon inclusion to generate distinct mRNA transcripts and modulate protein expression, exemplified by votoplam (PTC518)[22, 25, 29, 30] - PTC's PTSeek screening technology, leveraging learnings from SMA and HD programs, enables the discovery of novel sequence-selective 5' splice site enhancers for iExons[48, 96, 98] - PTC has discovered iExons throughout the entire transcriptome, covering a majority of genes, allowing for the targeting of splicing for novel small molecule enhancers[89, 90, 91] Splicing Platform Programs - MSH3 program targets nucleotide repeat disorders like Huntington's disease, with 30-50% MSH3 lowering stalling expansion in a human somatic expansion model[111, 129] - Spinocerebellar Ataxia 3 (SCA3) program aims to lower mutant ATXN3 protein production by inducing exon skipping[132, 141, 142] - Oncology program targets a key protein in cancer biology, with novel splicing modulators selectively inducing mRNA decay[147, 152] - Hemoglobinopathies program targets regulators of fetal hemoglobin (HbF) levels, with novel splicing modulators lowering a validated target of HbF induction[158, 163, 165] Inflammation & Ferroptosis Platform - PTC's inflammation and ferroptosis platform targets specialized enzyme hubs to regulate inflammation, energy production, and oxidative stress[179] - Parkinson's Disease program targets 15-LO to prevent ferroptosis-mediated cell death and alpha-synuclein aggregation[181, 183, 188] - PTC612, a highly selective NLRP3 inhibitor, demonstrates significant reduction in inflammatory cytokines and pathology across multiple preclinical models, with an IC50 of 099 nM in THP-1 cells[225, 227, 234]

Financial Performance - ITT reported Q3 2025 revenue of $999.1 million, a 12.9% increase compared to $885.2 million in Q3 2024[31] - Organic revenue growth for Q3 2025 was 6.1%[31] - Adjusted EPS for Q3 2025 was $1.78, a 21.1% increase compared to $1.47 in Q3 2024[43] - Free cash flow for Q3 2025 was $154.1 million, a 77% increase compared to $87.3 million in Q3 2024[17,53] - The company raised its full-year adjusted EPS guidance to a range of $6.62 to $6.68[16] Segment Performance (2024 Revenue) - Motion Technologies (MT) reported $1.4478 billion in revenue[26] - Industrial Process (IP) reported $1.361 billion in revenue[26] - Connect & Control Technologies (CCT) reported $825.1 million in revenue[26] Growth Metrics - The company achieved a 9% organic revenue CAGR and a 13% adjusted EPS CAGR over a 3-year period[11] - Average ROIC was 15%[11] - Total Shareholder Return (TSR) was +45%, outperforming the S&P 500 by +1,600 bps[11] Full Year 2024 vs 2021 (Organic) - Organic revenue grew by $805.3 million, a 30% increase[26] - Organic orders grew by $767.2 million, a 27% increase[28] Full Year 2025 Guidance - The company expects approximately $3.87 billion in revenue[53] - The company expects approximately $500 million in free cash flow[16,53]

Financial Performance - Q1 FY26 - Net sales decreased slightly by 0.4% to $7,840 million compared to $7,871 million in Q1 FY25 [14] - Adjusted EBITDA increased significantly by 24.6% to $167 million from $134 million in Q1 FY25 [14] - Adjusted EPS grew substantially by 250% to $0.56 from $0.16 in Q1 FY25 [14] - Free cash flow improved from $(159) million to $(54) million [14] Strategic Initiatives and Operational Efficiency - Network optimization actions reduced total net sales growth by approximately 3% [15, 24] - Net leverage ratio decreased to 3.2x, down 1.0x year-over-year [30] - Net debt decreased by $331 million year-over-year to $1,897 million [30] - Lean daily management was deployed at 34 out of 49 distribution centers by the end of the quarter [19] - New item setup time was reduced by 50% at the Chesterfield, NH Distribution Center [44] Fiscal Year 2026 Outlook - The company affirmed its fiscal 2026 outlook, including net sales of $31.6 - $32.0 billion and adjusted EBITDA of $630 - $700 million [36]

Financial Performance - Fiscal Year 2025 revenue was $27348 million, a decrease of 25% compared to $28058 million in Fiscal Year 2024[12] - Fiscal Year 2025 Adjusted EBITDA was $2574 million, down 271% from $3529 million in Fiscal Year 2024[12] - Q4 2025 revenue increased by 41% to $712 million compared to $6843 million in Q4 2024[12] - Q4 2025 Adjusted EBITDA decreased by 197% to $647 million compared to $805 million in Q4 2024[12] - Free cash flow for Fiscal Year 2025 was $58 million, a significant decrease of 964% compared to $1599 million in Fiscal Year 2024[12] - The company's net leverage ratio was 472x[6,30] Strategic Initiatives - The company is launching a multi-year strategic business transformation plan expected to generate annual cost savings of $75 million by the end of fiscal year 2026[6,37] - The transformation plan focuses on three pillars: Commercial Excellence, Operational Excellence, and Asset & Network Optimization[6,36] Fiscal Year 2026 Outlook - The company anticipates revenue of $27 billion[6] - The company anticipates Adjusted EBITDA in the range of $285 million to $315 million[6] - The company anticipates free cash flow in the range of $50 million to $60 million[6]

Acquisition Overview - PROG Holdings will acquire Purchasing Power for $420 million in cash[8, 34] - The acquisition is expected to contribute between $50 million and $60 million of Adjusted EBITDA in 2026[8] - The deal is anticipated to close in early 2026, pending regulatory approvals[34] Purchasing Power Highlights - Purchasing Power is a FinTech platform that allows consumers to buy goods and services over time via payroll deduction[12] - The company's 2026 revenue is projected to be between $680 million and $730 million[13, 34] - Approximately 90% of Purchasing Power's outstanding balance has payment terms of 12 months or less[14] - Purchasing Power has relationships with over 360 established employers[14, 19, 22, 28] - Purchasing Power has relationships with over 100 distribution partners[14, 19] - Purchasing Power reaches over 7 million eligible employees[14, 19, 22] - Purchasing Power has a 98% client revenue retention rate[14, 22] Strategic Benefits - The acquisition is expected to result in double-digit percentage EPS accretion in 2026[34] - PROG Holdings aims to maintain a net leverage ratio between 1.5x and 2.0x post-transaction[32, 34]